Rock Springs Capital VERA Position
Active9-Fund ConvergenceRock Springs Capital trimmed their position in Vera Therapeutics Inc. (VERA) in Q4 2025, holding $28.8M worth of shares across 568,579 shares.
The position was first reported in Q1 2024 and has been tracked across 8 quarterly 13F filings.
VERA is a convergence signal: 9 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Atacicept in 167 days (Sep 30, 2026), making the timing of Rock Springs's position particularly relevant.
Short interest stands at 13.1% of float with 7.0 days to cover, indicating significant bearish positioning against Rock Springs's long thesis.
About Vera Therapeutics Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Full company profile →Short Interest
13.1%
7.0 days to cover
Rock Springs Capital VERA Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 568,579 | -48,817 | $28.8M |
| Q3 2025 | Held | 617,396 | — | $17.9M |
| Q2 2025 | Increased | 617,396 | +96,600 | $14.5M |
| Q1 2025 | Increased | 520,796 | +32,933 | $12.5M |
| Q4 2024 | Increased | 487,863 | +104,371 | $20.6M |
| Q3 2024 | Increased | 383,492 | +2,300 | $16.9M |
| Q2 2024 | Increased | 381,192 | +40,024 | $13.8M |
| Q1 2024 | New | 341,168 | +341,168 | $14.7M |
Frequently Asked Questions
Does Rock Springs Capital own VERA?
Yes. As of Q4 2025, Rock Springs Capital holds 568,579 shares of Vera Therapeutics Inc. (VERA) valued at $28.8M. This data comes from their SEC 13F filing.
How many hedge funds own VERA?
9 specialist biotech hedge funds currently hold VERA, including Avoro Capital Advisors, Deerfield Management, Deep Track Capital and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy VERA?
Rock Springs Capital's position in VERA was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's VERA position increasing or decreasing?
Rock Springs Capital trimmed their VERA position in the most recent quarter, reducing by 48,817 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
VERACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →